Acromegaly News and Research

RSS
Acromegaly is a syndrome that results when the pituitary gland produces excess growth hormone (hGH) after epiphyseal plate closure at puberty.
ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Drugs often fail to bring acromegaly under control in routine clinical practice

Drugs often fail to bring acromegaly under control in routine clinical practice

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Chiasma, Roche enter agreement to develop and commercialize Octreolin

FDA approves Novartis Signifor injection for treatment of Cushing's disease

FDA approves Novartis Signifor injection for treatment of Cushing's disease

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

Gamma Knife surgery stops growth of 'World's tallest living human'

Gamma Knife surgery stops growth of 'World's tallest living human'

World's tallest living man stops growing at 8ft 3 inches

World's tallest living man stops growing at 8ft 3 inches

World's tallest man appears to have stopped growing after treatment at UVA

World's tallest man appears to have stopped growing after treatment at UVA

Ipsen total revenues increase 5.5% to €1,234.9M for the full year 2011

Ipsen total revenues increase 5.5% to €1,234.9M for the full year 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

New Acromegaly clinical practice guidelines

New Acromegaly clinical practice guidelines

Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress

Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress

Ipsen first quarter sales increase 6.1% to €285.8 million

Ipsen first quarter sales increase 6.1% to €285.8 million

FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly

FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

Allergan initiates AGN-214868 Phase II trials in post herpetic neuralgia and overactive bladder

Allergan initiates AGN-214868 Phase II trials in post herpetic neuralgia and overactive bladder

Endo fourth quarter total revenues increase 31% to $511 million

Endo fourth quarter total revenues increase 31% to $511 million

Researchers identify genetic mutation responsible for acromegaly disease

Researchers identify genetic mutation responsible for acromegaly disease

Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly

Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly